These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34623544)

  • 1. Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.
    Sabbah HN
    Heart Fail Rev; 2022 Sep; 27(5):1911-1923. PubMed ID: 34623544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
    Sabbah HN
    Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal evolution of the heart failure phenotype in Barth syndrome and treatment with elamipretide.
    Sabbah HN; Taylor C; Vernon HJ
    Future Cardiol; 2023 Mar; 19(4):211-225. PubMed ID: 37325898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
    Reid Thompson W; Hornby B; Manuel R; Bradley E; Laux J; Carr J; Vernon HJ
    Genet Med; 2021 Mar; 23(3):471-478. PubMed ID: 33077895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechano-energetic aspects of Barth syndrome.
    Dudek J; Maack C
    J Inherit Metab Dis; 2022 Jan; 45(1):82-98. PubMed ID: 34423473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical presentation and natural history of Barth Syndrome: An overview.
    Taylor C; Rao ES; Pierre G; Chronopoulou E; Hornby B; Heyman A; Vernon HJ
    J Inherit Metab Dis; 2022 Jan; 45(1):7-16. PubMed ID: 34355402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and future treatment approaches for Barth syndrome.
    Thompson R; Jefferies J; Wang S; Pu WT; Takemoto C; Hornby B; Heyman A; Chin MT; Vernon HJ
    J Inherit Metab Dis; 2022 Jan; 45(1):17-28. PubMed ID: 34713454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental models of Barth syndrome.
    Pu WT
    J Inherit Metab Dis; 2022 Jan; 45(1):72-81. PubMed ID: 34370877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.
    Van den Eynde J; Chinni B; Vernon H; Thompson WR; Hornby B; Kutty S; Manlhiot C
    Orphanet J Rare Dis; 2023 Apr; 18(1):76. PubMed ID: 37041653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiolipin remodeling in Barth syndrome and other hereditary cardiomyopathies.
    Bertero E; Kutschka I; Maack C; Dudek J
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165803. PubMed ID: 32348916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
    Thompson WR; Manuel R; Abbruscato A; Carr J; Campbell J; Hornby B; Vaz FM; Vernon HJ
    Genet Med; 2024 Jul; 26(7):101138. PubMed ID: 38602181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiolipin metabolism and its causal role in the etiology of the inherited cardiomyopathy Barth syndrome.
    Gaspard GJ; McMaster CR
    Chem Phys Lipids; 2015 Dec; 193():1-10. PubMed ID: 26415690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
    Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
    J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Barth syndrome: cardiolipin, cellular pathophysiology, management, and novel therapeutic targets.
    Zegallai HM; Hatch GM
    Mol Cell Biochem; 2021 Mar; 476(3):1605-1629. PubMed ID: 33415565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial cardiolipin involved in outer-membrane protein biogenesis: implications for Barth syndrome.
    Gebert N; Joshi AS; Kutik S; Becker T; McKenzie M; Guan XL; Mooga VP; Stroud DA; Kulkarni G; Wenk MR; Rehling P; Meisinger C; Ryan MT; Wiedemann N; Greenberg ML; Pfanner N
    Curr Biol; 2009 Dec; 19(24):2133-9. PubMed ID: 19962311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PPAR pan-agonist bezafibrate ameliorates cardiomyopathy in a mouse model of Barth syndrome.
    Huang Y; Powers C; Moore V; Schafer C; Ren M; Phoon CK; James JF; Glukhov AV; Javadov S; Vaz FM; Jefferies JL; Strauss AW; Khuchua Z
    Orphanet J Rare Dis; 2017 Mar; 12(1):49. PubMed ID: 28279226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.
    Ikon N; Ryan RO
    Lipids; 2017 Feb; 52(2):99-108. PubMed ID: 28070695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficiency in Cardiolipin Reduces Doxorubicin-Induced Oxidative Stress and Mitochondrial Damage in Human B-Lymphocytes.
    Aryal B; Rao VA
    PLoS One; 2016; 11(7):e0158376. PubMed ID: 27434059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
    Hornby B; Thompson WR; Almuqbil M; Manuel R; Abbruscato A; Carr J; Vernon HJ
    Orphanet J Rare Dis; 2022 Sep; 17(1):336. PubMed ID: 36056411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.
    Koenig MK; Russo SN; McBride KL; Bjornsson HT; Gunnarsdottir BB; Goldstein A; Falk SA
    JIMD Rep; 2023 Jan; 64(1):65-70. PubMed ID: 36636586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.